Inhibition of Metastatic Spread by I.C.R.F. 159: Selective Deletion of a Malignant Characteristic
- 7 November 1970
- Vol. 4 (5731), 344-346
- https://doi.org/10.1136/bmj.4.5731.344
Abstract
Treatment with I.C.R.F. 159 completely inhibited metastasis formation in mice implanted with Lewis lung carcinoma at doses having little influence on the rate of growth of the primary implant. This inhibition was due to the effect of I.C.R.F. 159 on the development of blood vessels of the invading margins of the primary tumour. So far as is known, this is the first time a drug has induced a specific loss of the malignant characteristic of blood-borne tumour cell dissemination.This publication has 12 references indexed in Scilit:
- Drug-induced inhibition of tumour cell dissemination.1970
- Mode of Action of the Cytostatic Agent ‘ICRF 159’Nature, 1970
- Effect of ICRF 159 on the Mammalian Cell Cycle: Significance for Its Use in Cancer ChemotherapyJNCI Journal of the National Cancer Institute, 1970
- Antitumour Activity in a Series of bisDiketopiperazinesNature, 1969
- Preliminary Clinical Assessment of I.C.R.F. 159 in Acute Leukaemia and LymphosarcomaBMJ, 1969
- Effect of Triton WR 1339 on cancer dissemination and metastasesEuropean Journal of Cancer (1965), 1969
- Quantitative studies on cancer dissemination.1969
- Cancer Chemotherapy and SurgerySurgical Clinics of North America, 1968
- The antitumour activity of a series of benzothiophenesBiochemical Pharmacology, 1967
- CHEMOTHERAPY STUDIES ON PRIMARY TUMOR GRAFTS AND METASTASES IN HAMSTERS AND MICE.1964